知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

26 records (took 0.017 seconds)

    GENETIC MARKER FOR EARLY BREAST CANCER PROGNOSIS PREDICTION AND DIAGNOSIS, AND USE THEREOF
    11.
    发明申请
    GENETIC MARKER FOR EARLY BREAST CANCER PROGNOSIS PREDICTION AND DIAGNOSIS, AND USE THEREOF 审中-公开

    公开(公告)号：US20190040473A1

    公开(公告)日：2019-02-07

    申请号：US16155220

    申请日：2018-10-09

    Applicant: GENCURIX INC.

    Inventor： Young Kee SHIN ,  Young-Deug KIM ,  En Sel OH ,  Jun Young CHOI ,  Sang Rea CHO

    IPC: C12Q1/6886

    Abstract: The present invention relates to a gene for predicting or diagnosing the prognosis of early-stage breast cancer and to a use thereof, and more specifically relates to a genetic marker for predicting or diagnosing the prognosis of breast cancer, including TRBC1 (T cell receptor beta constant 1), BTN3A2 (butyrophilin, subfamily 3, member A2) or HLA-DPA1 (major histocompatibility complex, class II, DP alpha 1) for providing information necessary for predicting or diagnosing the prognosis of a breast cancer patient. The genetic marker of the present invention allows the prediction or diagnosis of the prognosis of a breast cancer patient, and can therefore advantageously be used for the purpose of providing a direction as to the future course of breast cancer treatment, including a decision on whether anticancer therapy is necessary.

    GENE FOR PREDICTING THE PROGNOSIS FOR EARLY-STAGE BREAST CANCER, AND A METHOD FOR PREDICTING THE PROGNOSIS FOR EARLY-STAGE BREAST CANCER BY USING THE SAME
    12.
    发明申请
    GENE FOR PREDICTING THE PROGNOSIS FOR EARLY-STAGE BREAST CANCER, AND A METHOD FOR PREDICTING THE PROGNOSIS FOR EARLY-STAGE BREAST CANCER BY USING THE SAME 审中-公开
    用于预测早期乳腺癌预后的基因，以及通过使用该方法预测早期乳腺癌的预后的方法

    公开(公告)号：US20130344482A1

    公开(公告)日：2013-12-26

    申请号：US13935502

    申请日：2013-07-04

    Applicant: Gencurix Inc.

    Inventor： Young Kee Shin ,  Yoon La Choi ,  Young-Deug Kim ,  Eu Sel Oh ,  Si Eun Kim

    IPC: C12Q1/68

    CPC classification number: C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/57415 ,  G01N33/57484 ,  G01N2333/723 ,  G16B25/00

    Abstract: The present invention relates to a method for selecting a gene intended to predict the prognosis for a cancer, to the selected gene for predicting the prognosis of cancer and to a kit for predicting and a method for predicting metastasis in breast-cancer patients by using the same. In the present invention, a straight forward method is used to achieve high-reliability prediction of the patient's prognosis by analysing for the genetic characteristics of early stage breast cancer, and thus the present invention can be used to advantage in prognosis diagnosis which can reduce unnecessary anticancer therapy.

    Abstract translation: 本发明涉及选择用于预测癌症预后的基因的方法，所选择的用于预测癌症预后的基因和用于预测的试剂盒和用于预测乳腺癌患者转移的方法的方法，所述方法通过使用 相同。 在本发明中，通过分析早期乳腺癌的遗传特征，使用直接法来实现患者预后的高可靠性预测，因此本发明可以用于预后诊断中，可以减少不必要的 抗癌治疗。

    METHOD FOR PREDICTING PROGNOSIS OF BREAST CANCER PATIENT
    14.
    发明申请
    METHOD FOR PREDICTING PROGNOSIS OF BREAST CANCER PATIENT 审中-公开

    公开(公告)号：US20200071768A1

    公开(公告)日：2020-03-05

    申请号：US16462655

    申请日：2017-11-21

    Applicant: GENCURIX INC.

    Inventor： Sang Rae CHO ,  Young Ho MOON ,  Jin Il HAN ,  Young Kee SHIN

    IPC: C12Q1/6886

    Abstract: The present invention relates to a method for predicting the prognosis of a breast cancer patient. More specifically, to provide information needed to predict the prognosis of a breast cancer patient, the method for predicting the prognosis of breast cancer including the following steps of the present invention comprises: (a) obtaining a biological sample from a breast cancer patient; (b) measuring the mRNA expression level of matrix metallopeptidase 11 (MMP11) and the mRNA expression level of cluster of differentiation 2 (CD2) from patient information or the sample of step (a); (c) normalizing the gene mRNA expression levels selected and measured in step (b); and (d) predicting the prognosis of breast cancer by combining the gene expression levels normalized in step (c), wherein overexpression of the MMP11 indicates a bad prognosis, and overexpression of CD2 indicates a good prognosis.The method of the present invention has an effect of being capable of more accurately predicting the future prognosis of metastasis, recurrence, or metastatic recurrence in breast cancer patients, and in particular, has a very excellent ability to predict the prognosis of HER2-type breast cancer, the prognosis of which is very poor, and thus can be usefully used to provide clues for the direction of future treatment of breast cancer.

    GENETIC MARKER FOR EARLY BREAST CANCER PROGNOSIS PREDICTION AND DIAGNOSIS, AND USE THEREOF
    18.
    发明申请
    GENETIC MARKER FOR EARLY BREAST CANCER PROGNOSIS PREDICTION AND DIAGNOSIS, AND USE THEREOF 审中-公开
    遗传标记用于早期乳腺癌预后和诊断及其使用

    公开(公告)号：US20160102359A1

    公开(公告)日：2016-04-14

    申请号：US14886948

    申请日：2015-10-19

    Applicant: GENCURIX INC.

    Inventor： Young Kee SHIN ,  Young-Deug Kim ,  En Sel Oh ,  Jun Young Choi ,  Sang Rea Cho

    IPC: C12Q1/68

    CPC classification number: C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/57415 ,  G01N2800/52

    Abstract: A gene for predicting or diagnosing the prognosis of early-stage breast cancer and to a use thereof is disclosed, and more specifically a genetic marker for predicting or diagnosing the prognosis of breast cancer, including TRBC1 (T cell receptor beta constant 1), BTN3A2 (butyrophilin, subfamily 3 member A2) or HLA-DPA1 (major histocompatibility complex, class II, DP alpha 1) for providing information necessary for predicting or diagnosing the prognosis of a breast cancer patient. The genetic marker allows the prediction or diagnosis of the prognosis of a breast cancer patient, and can therefore advantageously be used for the purpose of providing a direction as to the future course of breast cancer treatment, including a decision on whether anticancer therapy is necessary.

    Abstract translation: 公开了一种用于预测或诊断早期乳腺癌预后的基因及其用途，更具体地，涉及用于预测或诊断乳腺癌预后的遗传标记，包括TRBC1（T细胞受体β常数1），BTN3A2 （雌激素，亚家族3成员A2）或HLA-DPA1（主要组织相容性复合物，II类，DPα1），用于提供预测或诊断乳腺癌患者预后所需的信息。 遗传标记允许预测或诊断乳腺癌患者的预后，因此可以有利地用于为乳腺癌治疗的未来方向提供方向，包括是否需要抗癌治疗的决定。

Patent Agency Ranking